Literature DB >> 16850447

Standard versus adaptive monitoring procedures: A commentary.

Thomas R Fleming1.   

Abstract

In the standard approach to designing definitive clinical trials, the primary endpoint and test statistic to be used for the primary analysis are specified before trial initiation. The false positive error rate for the null hypothesis and statistical power to detect the targeted size of treatment effect are also specified. Standard monitoring procedures, such as the group sequential guidelines, enable interim monitoring while maintaining the integrity of this approach. In contrast, adaptive monitoring procedures seek to provide flexibility to modify these pre-specified design features during the course of the trial. However, these procedures have several undesirable properties, including lesser statistical efficiency, reduced interpretability of primary outcome results, basing design changes on unreliable interim estimates of efficacy, risks to the integrity and credibility of the trial, loss of flexibility to use emerging results from external sources to alter key design features, and overemphasis of the importance of statistical significance relative to clinical significance. Copyright 2006 John Wiley & Sons, Ltd.

Mesh:

Year:  2006        PMID: 16850447     DOI: 10.1002/sim.2641

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

1.  Issues in using progression-free survival when evaluating oncology products.

Authors:  Thomas R Fleming; Mark D Rothmann; Hong Laura Lu
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

2.  A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens.

Authors:  Peter B Gilbert; Douglas Grove; Erin Gabriel; Ying Huang; Glenda Gray; Scott M Hammer; Susan P Buchbinder; James Kublin; Lawrence Corey; Steven G Self
Journal:  Stat Commun Infect Dis       Date:  2011-10

3.  Predicting clinical trial results based on announcements of interim analyses.

Authors:  Kristine R Broglio; David N Stivers; Donald A Berry
Journal:  Trials       Date:  2014-03-07       Impact factor: 2.279

Review 4.  Sharing interim trial results by the Data Safety Monitoring Board with those responsible for the trial's conduct and progress: a narrative review.

Authors:  Victoria Borg Debono; Lawrence Mbuagbaw; Lehana Thabane
Journal:  Trials       Date:  2017-03-09       Impact factor: 2.279

Review 5.  Advancing Clinical Trials for Inherited Retinal Diseases: Recommendations from the Second Monaciano Symposium.

Authors:  Debra A Thompson; Alessandro Iannaccone; Robin R Ali; Vadim Y Arshavsky; Isabelle Audo; James W B Bainbridge; Cagri G Besirli; David G Birch; Kari E Branham; Artur V Cideciyan; Steven P Daiger; Deniz Dalkara; Jacque L Duncan; Abigail T Fahim; John G Flannery; Roberto Gattegna; John R Heckenlively; Elise Heon; K Thiran Jayasundera; Naheed W Khan; Henry Klassen; Bart P Leroy; Robert S Molday; David C Musch; Mark E Pennesi; Simon M Petersen-Jones; Eric A Pierce; Rajesh C Rao; Thomas A Reh; Jose A Sahel; Dror Sharon; Paul A Sieving; Enrica Strettoi; Paul Yang; David N Zacks
Journal:  Transl Vis Sci Technol       Date:  2020-06-03       Impact factor: 3.283

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.